anti-CLL1 CAR-T

Anti-CLL1 CAR-T is an autologous chimeric antigen receptor (CAR) T-cell therapy engineered to target C-type lectin-like molecule 1 (CLL1, also known as CLEC12A), a surface antigen highly expressed on acute myeloid leukemia (AML) blasts and leukemia stem cells but not on normal hematopoietic stem cells. The therapy involves collecting a patient's own T-cells, genetically modifying them to express a synthetic receptor that recognizes CLL1, and reinfusing them after lymphodepleting chemotherapy. Upon binding to CLL1-expressing AML cells, the modified T-cells become activated and mediate cytotoxicity through cytokine secretion and direct killing mechanisms. Clinical trials in pediatric patients with relapsed or refractory AML have shown promising efficacy with manageable toxicity profiles, including cytokine release syndrome of grade 1–2 severity[2][4][5][7]. Multiple generations of constructs exist; some incorporate additional co-stimulatory domains or safety switches for enhanced activity or control[3][5].

Other names

anti-CLL1 CAR T-cellanti-CLL-1 CAR T-cellanti-CLL 1 CAR T-cellCLL1 CAR-T cell therapyCLL-1 CAR-T cell therapyCLL 1 CAR-T cell therapyCLL1-chimeric antigen receptor T cellsCLL-1-chimeric antigen receptor T cellsCLL 1-chimeric antigen receptor T cells